Technical Analysis for CRDL - Cardiol Therapeutics Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Strong but Oversold | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | -3.11% | |
| NR7 | Range Contraction | -3.11% | |
| Narrow Range Bar | Range Contraction | -3.11% | |
| Wide Bands | Range Expansion | -3.11% | |
| Fell Below 20 DMA | Bearish | -2.90% | |
| Wide Bands | Range Expansion | -2.90% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | about 14 hours ago |
| Down 3% | about 14 hours ago |
| Down 2% | about 14 hours ago |
| Down 1% | about 14 hours ago |
| Possible NR7 | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 2024-05-17
Cardiol Therapeutics Inc Description
Cardiol Therapeutics Inc is a Canada-based company engaged in the pharmaceutical business sector. The Company is focused on the research and commercial development of pharmaceutical cannabidiol products and targeted therapies for heart failure and cancer. It has research programs focused on development of nanotherapeutics to treat heart failure underway. The Company invests in development of formulations for three medical markets: commercializing a line of purity pharmaceutically-manufactured cannabidiol products in the market for medical cannabinoids; development of nanotechnologies designed to deliver cannabinoids and other anti-inflammatory drugs for the treatment of heart failure, a cause of death and hospitalization, and pursuing an immunotherapeutics program commencing with a cancer immunotherapeutic in combination with cannabinoids for treating Glioblastoma Multiforme.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharma Pharmaceutical Drug Cancer Drugs Heart Organ Systems Cannabinoid Blastoma Cannabidiol Cannabinoids Analgesics Glioblastoma Pharmaceutical Business Sector
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.94 |
| 52 Week Low | 0.74 |
| Average Volume | 166,325 |
| 200-Day Moving Average | 1.493 |
| 50-Day Moving Average | 2.191 |
| 20-Day Moving Average | 2.445 |
| 10-Day Moving Average | 2.514 |
| Average True Range | 0.182 |
| RSI (14) | 48.98 |
| ADX | 32.17 |
| +DI | 22.394 |
| -DI | 18.205 |
| Chandelier Exit (Long, 3 ATRs) | 2.275 |
| Chandelier Exit (Short, 3 ATRs) | 2.485 |
| Upper Bollinger Bands | 2.853 |
| Lower Bollinger Band | 2.037 |
| Percent B (%b) | 0.37 |
| BandWidth | 33.377 |
| MACD Line | 0.084 |
| MACD Signal Line | 0.122 |
| MACD Histogram | -0.0375 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.505 | ||||
| Resistance 3 (R3) | 2.510 | 2.460 | 2.478 | ||
| Resistance 2 (R2) | 2.460 | 2.418 | 2.458 | 2.468 | |
| Resistance 1 (R1) | 2.400 | 2.392 | 2.375 | 2.395 | 2.459 |
| Pivot Point | 2.350 | 2.350 | 2.338 | 2.348 | 2.350 |
| Support 1 (S1) | 2.290 | 2.308 | 2.265 | 2.285 | 2.221 |
| Support 2 (S2) | 2.240 | 2.282 | 2.238 | 2.212 | |
| Support 3 (S3) | 2.180 | 2.240 | 2.203 | ||
| Support 4 (S4) | 2.175 |
